Beam Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates across key financial lines, with revenue of $0.49M significantly below the expected $17.20M due to lower collaboration income. Net loss per share (GAAP) of -$1.18 was wider than the -$1.10 expected, primarily driven by the revenue shortfall and non-cash derivative fair value adjustments. However, clinical execution remains strong with the first patient dosed in the BEAM-302 pivotal cohort and a robust cash balance of $1.2B extending the runway into mid-2029.